Bridge Biotherapeutics has rebranded itself as Parataxis Korea, marking a strategic pivot towards a digital asset treasury business. According to NS3.AI, this change comes in the wake of a sale of management rights and a comprehensive business restructuring. The decision follows the unsuccessful development of the company's primary biotech pipeline, prompting a shift in business strategy.